FDA Approves New Device for Chronic, Moderate-to-Severe Heart Failure
Optimizer Smart system approved for patients with chronic heart failure not eligible for tx with other devices.
Topics
TOPICS
Short-Term Mortality After Acute MI on the Decline
Short-term mortality and readmission rates after acute MI have improved during the last 20 years among Medicare beneficiaries.
Reassessing the Upper Limit of Normal in High Sensitivity Cardiac Troponin I Assays
Greater scrutiny is needed in evaluating high sensitivity cardiac troponin I levels for the purpose of excluding or diagnosing acute myocardial infarction.
Riociguat Therapy Linked to Improved Clinical Parameters in Inoperable CTEPH
Riociguat has been shown to reduce clinical worsening in patients with technical inoperable and residual chronic thromboembolic pulmonary hypertension.
Clinical Trials for Cancer Therapies Lack Data on Patients With Cardiovascular Disease
While 1 in 3 trials on cancer treatment excluded patients with cardiovascular disease, definitions and reasoning for exclusion were not well documented.
Trastuzumab Tied to Higher Long-Term Risk for Heart Failure
Increased risk for heart failure seen in breast cancer survivors given trastuzumab rather than chemo alone.
Pregnancy-Adapted Algorithm Avoids Diagnostic Imaging for PE
Suspected pulmonary embolism safely ruled out in some pregnant women with diagnostic algorithm.
Making the Case for Earlier Palliative Care in PAH: A Clinical Opinion
A clinician shares his experience with palliative care in cardiology and makes the case for offering palliative care services earlier in pulmonary arterial hypertension.
Supraflex Noninferior to Xience for Reducing Device-Related Complications After PCI
The sirolimus-eluting Supraflex coronary stent with absorbable polymer coating was noninferior to a currently best-in-class drug-eluting stent at 12 months.
Rivaroxaban Reduces Post-Stroke Mortality Risk in Nonvalvular Afib
Rivaroxaban found to reduce risk of stroke.
No Difference Between Antiplatelet Agents vs Anticoagulants in Recurrent Stroke Risk After Cervical Dissection
Researchers found a low rate of recurrent stroke after carotid and vertebral dissection and no difference between antiplatelet agents and anticoagulants.
Depression, Antidepressants, and Atrial Fibrillation: What Do We Know?
Researchers found that patients who have atrial fibrillation are more likely to have a history of depression than patients who do not.
Balloon Pulmonary Angioplasty Safely Treats CTEPH in Older Patients
Balloon pulmonary angioplasty was considered safe and effective even in patients considered “oldest-old” with chronic thromboembolic pulmonary hypertension.
Do CAD Outcomes Differ Between Those Enrolled in Medicare Advantage vs Fee-for-Service Medicare?
Researchers found that patients with coronary artery disease enrolled in Medicare Advantage had a slightly higher comorbidity burden and received higher quality care than their traditional fee-for-service Medicare counterparts.
Mild Depression Predictive of All-Cause Mortality After MI
Patients with depressive symptoms, however mild, face increased mortality risk long after an acute myocardial infarction.
Clinical Outcomes Compared With Generics, Brand-Name Drugs for Chronic Conditions
An analysis found comparable clinical outcomes among patients who initiated generics vs those who were treated with brand-name drugs for chronic conditions.
Tacrolimus Granules Now Available for Patients Who Have Difficulty Swallowing Capsules
A new granule formulation of Prograf has been made available for the prophylaxis of organ rejection.
CAD Risk Reduced With Statin Use in Asthma-COPD Overlap Syndrome
The risk for coronary artery disease in patients with asthma-COPD overlap syndrome who used statins was lower regardless of the duration of treatment.
Sleep Apnea Severity Linked to Elevated Pulmonary Capillary Wedge Pressure
Sleep apnea severity was associated with elevated pulmonary capillary wedge pressure in adults.
Antithrombotic Regimens Evaluated in Patients With Nonvalvular Afib After ACS or PCI
Results from the phase 4 AUGUSTUS trial, evaluating apixaban vs vitamin K antagonists in patients with nonvalvular atrial fibrillation and recent ACS and/or undergoing PCI.
Want to read more?
Please login or register first to view this content.
Next post in Heart Failure
